NEW YORK, August 10, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Immunomedics Inc. (NASDAQ: IMMU), Vertex
Pharmaceuticals Inc. (NASDAQ: VRTX), Opexa Therapeutics Inc.
(NASDAQ: OPXA), Oncolytics Biotech Inc. (NASDAQ: ONCY), and IGI
Laboratories Inc. (AMEX: IG). Free research report on Immunomedics
can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=IMMU On
Friday, August 07, 2015, the NASDAQ
Composite ended at 5,043.54, down 0.26%, the Dow Jones Industrial
Average lost 0.27%, to finish the day at 17,373.38, and the S&P
500 closed at 2,077.57, down 0.29%. The losses were broad based as
eight out of nine sectors ended the session in negative. Register
for your complimentary reports at the links given below.
Immunomedics Inc.'s stock lost 3.19%, to close the day at
$1.82. The stock recorded a trading
volume of 1.36 million shares, below its three months average
volume of 1.61 million shares. Over the last one month and over the
past three months, Immunomedics Inc.'s shares have plummeted 54.04%
and 54.27%, respectively. Furthermore, the stock has lost 62.08%
since the start of this year. The company's shares are trading
52.06% below their 50-day moving average. Additionally,
Immunomedics Inc. has a Relative Strength Index (RSI) of 12.99.
Sign up and read the free notes on IMMU at:
https://www.EquityResearchInstitute.com/reports?keyword=IMMU
On Friday, shares in Vertex Pharmaceuticals Inc. recorded a
trading volume of 2.44 million shares, higher than their three
months average volume of 1.59 million shares. The stock ended the
day 1.22% lower at $137.74. Vertex
Pharmaceuticals Inc.'s stock has surged 13.94% in the last one
month, 10.15% in the previous three months and 15.94% on YTD basis.
The company is trading above its 50-day and 200-day moving averages
by 7.22% and 13.09%, respectively. Furthermore, shares of Vertex
Pharmaceuticals Inc. have an RSI of 59.25. The complimentary notes
on VRTX can be downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=VRTX
Opexa Therapeutics Inc.'s stock lost 5.93%, to close Friday's
session at $0.38. The stock recorded
a trading volume of 0.12 million shares, much below its three
months average volume of 1.53 million shares. Over the last one
month and the previous three months, Opexa Therapeutics Inc.'s
shares have lost 15.33% and 1.01%, respectively. Additionally, the
stock has plummeted 47.08% since the start of this year. The
company is trading 20.62% and 40.66% below its 50-day and 200-day
moving averages, respectively. Furthermore, Opexa Therapeutics
Inc.'s stock has an RSI of 35.07. Register for free on Equity
Research Institute and access the latest research on OPXA at:
https://www.EquityResearchInstitute.com/reports?keyword=OPXA
Oncolytics Biotech Inc.'s stock finished Friday's session 1.82%
higher at $0.56. A total of 0.19
million shares were traded, which was below its three months
average volume of 0.67 million shares. Over the last one month and
since the beginning of 2015, Oncolytics Biotech Inc.'s shares have
gained 1.82% and 5.66%, respectively. However, the stock has
plummeted 25.33% in the previous three months. The company's shares
are trading below their 50-day and 200-day moving averages by 7.13%
and 13.79%, respectively. Oncolytics Biotech Inc.'s stock has an
RSI of 43.75. The complete research on ONCY is available for free
at:
https://www.EquityResearchInstitute.com/reports?keyword=ONCY
On Friday, shares in IGI Laboratories Inc. ended the session
3.56% lower at $8.13. The stock
reported a trading volume of 0.49 million shares, below its three
months average volume of 0.61 million shares. Shares of the company
traded at a PE ratio of 29.04. IGI Laboratories Inc.'s shares have
surged 25.46% in the last one month and 61.63% in the previous
three months. However, the stock has lost 7.61% on YTD basis. The
company is trading 16.89% above its 50-day moving average.
Moreover, shares of IGI Laboratories Inc. have an RSI of 57.88.
Free in-depth research on IG is available at:
https://www.EquityResearchInstitute.com/reports?keyword=IG
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com